Provided by Tiger Trade Technology Pte. Ltd.

Merck

119.37
+3.002.58%
Pre-market: 119.400.0300+0.03%08:15 EDT
Volume:10.22M
Turnover:1.22B
Market Cap:296.28B
PE:16.40
High:120.12
Open:117.30
Low:116.80
Close:116.37
52wk High:125.14
52wk Low:73.31
Shares:2.48B
Float Shares:2.48B
Volume Ratio:0.75
T/O Rate:0.41%
Dividend:3.24
Dividend Rate:2.71%
EPS(TTM):7.28
EPS(LYR):7.28
ROE:36.88%
ROA:12.04%
PB:5.63
PE(LYR):16.40

Loading ...

Wells Fargo Adjusts Price Target on Merck & Co. to $150 From $135, Maintains Overweight Rating

MT Newswires Live
·
Mar 12

Merck & Co Inc : Wells Fargo Raises Target Price to $150 From $135

THOMSON REUTERS
·
Mar 12

Merck price target raised to $150 from $135 at Wells Fargo

TIPRANKS
·
Mar 12

Barclays Sticks to Their Hold Rating for Merck KGaA (0O14)

TIPRANKS
·
Mar 12

Merck's Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says

MT Newswires Live
·
Mar 11

Merck KGaA (0O14) Receives a Hold from Barclays

TIPRANKS
·
Mar 09

These 8 drugs could help fight dementia - and they're already on the market

Dow Jones
·
Mar 07

How to Get the Best Deals On Prescription Drugs -- Barron's

Dow Jones
·
Mar 07

Kepler Capital Keeps Their Buy Rating on Merck KGaA (0O14)

TIPRANKS
·
Mar 07

Leading Pharmaceutical Firms Race to Launch Oral Weight-Loss Medications

Deep News
·
Mar 06

FACTBOX-Top pharma companies racing to launch a weight-loss pill

Reuters
·
Mar 06

Outgoing Merck CEO Highlights Chinese Biotech Innovation in Final Earnings Call

Deep News
·
Mar 06

Merck & Co Inc Stock (MRK) Moved Down by 3.01% on Mar 5: A Full Analysis

TradingKey
·
Mar 05

Dow's 400-Point Fall Led By Losses In Shares Of Walmart, Merck

Dow Jones
·
Mar 05

Barclays Keeps Their Hold Rating on Merck KGaA (0O14)

TIPRANKS
·
Mar 05

J.P. Morgan Sticks to Their Buy Rating for Merck & Company (MRK)

TIPRANKS
·
Mar 05

Merck KGaA sees earnings drop on currency effects, MS drug

Reuters
·
Mar 05

Prescription Drug Prices Can Break the Bank. How to Get the Best Deals. -- Barrons.com

Dow Jones
·
Mar 05

Merck Exec Says Keytruda Loss of Exclusivity Seen as 'More of a Hill Than a Cliff' With Shallow Sales Dip Before Returning to Strong Growth

THOMSON REUTERS
·
Mar 04

Merck Exec Says Animal Health Business Revenues Expected to More Than Double by Mid-2030S - TD Cowen Conference

THOMSON REUTERS
·
Mar 04